INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mr. Cooper Group Inc. – COOP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mr. Cooper Group Inc. – COOP GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Mr. Cooper Group Inc. (“Mr. Cooper” or the “Company”) (NASDAQ: COOP). Such investors are advised […]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Molina Healthcare, Inc. of Class Action Lawsuit and Upcoming Deadlines – MOH

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Molina Healthcare, Inc. of Class Action Lawsuit and Upcoming Deadlines – MOH GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina” or the

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in WPP Plc of Class Action Lawsuit and Upcoming Deadlines – WPP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in WPP Plc of Class Action Lawsuit and Upcoming Deadlines – WPP GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc (“WPP” or the “Company”) (NYSE:

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RCI Hospitality Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – RICK

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RCI Hospitality Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – RICK GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. (“RCI”

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in KBR, Inc. of Class Action Lawsuit and Upcoming Deadlines – KBR

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in KBR, Inc. of Class Action Lawsuit and Upcoming Deadlines – KBR GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE:

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in VF Corporation of Class Action Lawsuit and Upcoming Deadlines – VFC

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in VF Corporation of Class Action Lawsuit and Upcoming Deadlines – VFC GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against VF Corporation (“VFC” or the “Company”) (NYSE:

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ATYR

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ATYR GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ:

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire October 24, 2025 Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule MYB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. – ARCT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. – ARCT GlobeNewswire October 24, 2025 NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. (“Arcturus” or the “Company”) (NASDAQ: ARCT). Such investors are advised to

Scroll to Top